Critical assessment of the global epidemiology of HCV (how reliable is the global HCV prevalence data?)

Size: px
Start display at page:

Download "Critical assessment of the global epidemiology of HCV (how reliable is the global HCV prevalence data?)"

Transcription

1 Critical assessment of the global epidemiology of HCV (how reliable is the global HCV prevalence data?) Prof. Peter Ferenci Medical University of Vienna Austria

2 There are two types of claims: those based on hard numbers and those based on slippery numbers. Simon Sinek

3 How frequent is Hepatitis C virus infection? -2017: Mill. infected worldwide 2018: 70 Mill. infected worldwide Where are the missing100 Mill.? Do they exist? no reliable epidemiology is available worldwide Computer games are presented How realistic it the plan of WHO to eliminate der HCV until 2030?

4 The first estimate Based on 300 publications from the late 80 s Expert meeting in Amsterdam Assumptions for disease progression (linear vs. nonlinear), changes in trend, age at infection DISMOD (computer program used) works best for chronic diseases (e.g., asthma). It is less adapted for infectious disease such as hepatitis C Factors modifying natural history not considered Consistently normal ALT levels. Steatohepatitis Alcohol intake HIV coinfection. HBV coinfection (HBsAg). The Global Burden of Hepatitis C Working Group, J Clin Pharm 2004

5 Precise estimation of the incidence of HCV infection is not possible given available data Estimate: 130 Mill. globally infected The Global Burden of Hepatitis C Working Group, J Clin Pharm 2004

6 Estimated Global seroprevalence: 184 Mill,

7 Global prevalence of HCV The total global prevalence of anti-hcv was estimated to be 1.6% ( %), corresponding to 115 (92-149) million past viraemic infections The majority of these infections, 104 (87-124) million, were among adults (defined as those older than 15 years old) with an anti-hcv infection rate of 2.0% ( %) The viraemic (RNA positive) prevalence was forecasted to be 1.1% ( %), corresponding to 80 (64-103) = million 80 Mill. viraemic HCV-PCR+ infections Again, most of these viraemic infections were among adults who accounted for 75 (62-89) million viraemic infections or a viraemic prevalence of 1.4% ( %) Gower et al, J. Hepatol Razavi H. Lancet 2017

8 Global prevalence and genotype distribution of HCV infection in 2015: a modelling study Estimate: 71 Mill. infected If your experiment needs a statistician, you need a better experiment. Ernest Rutherford Polaris Study, Lancet Gastroenterology Hepatology 2017

9 Global prevalence and genotype distribution of HCV infection in 2015: a modelling study 80%=57 Mill 20%=14 Mill/4 billion people = 3,500/Mill people Estimate: 71 Mill. infected Europe If your experiment needs a statistician, you need a better experiment. Ernest Rutherford Polaris Study, Lancet Gastroenterology Hepatology 2017

10 N Blood+ plasma Spont. clearance 10-30% Liver mortality ~10%/40a

11 Change in the transmission of HCV Blood, blood products, nosocomial Baby boomer iv.drugs Identification of HCV iv.drugs, HIV

12 -~1968 blood,+ plasma N Spont. clearance 10-30% Liver mortality ~10%/40a

13 Blood transfusion associated HCV infection Open heart surgery in the US Open heart surgery became popular in the late 70 ies, before transfusion were mostly used in trauma cases (war! WW2), major abdominal surgery 1996 USA: 600,000; 2006:700,000/year, higher incidence in the age group > 70a Assuming 200,000 blood transfusions in the 70 ies (heart+other) 45% HCV infection= 90,000/year, about 1 million/10 years Most likely none of them are living today The few children and young adults are now in their 60 ies and 70 s 1991 UK: ~ 18,000, 2007: ~ 17, Germany: 91,967 (all with ECC) German Society for Thoracic and Cardiovascular Surgery After 1982: HCV testing for blood donation, thus transfusion associated transmission should be zero

14 Blood transfusions in the USA USA About 11.5 Mill Units blood transfused/year About 3 units / patient =3.9 Mill. Recipients/year/US ~2-3 % PTH = cases of HCV/year until 1992 Use in hospitals since 1947 Peak 1984 UK Surgenor et al, NEJM 2000, Ellingson et al, Transfusion 2017

15 Plasma products F VIII/F IX substitution Fresh frozen plasma Human albumin outbreak of HCV infection of plasma donors in Austria und Germany (about 4,000) pooled plasma 80 s imported plasma from Africa Hämophiliacs died of HIV!

16 Other routes of infection Barbers, dentists important in developing countries, now legally controlled in Western countries Tatoos now regulated in most Western countries Sexual transmission high in MSM,HIV+ Impact on numbers unknown, regional differences

17 Change in the transmission of HCV Blood, blood products, nosocomial Baby boomer iv.drugs Identification of HCV iv.drugs, HIV

18 blood,+ plasma N Spont. clearance 10-30% Liver mortality ~10%/40a

19 The Vietnam war Men who were sent to Vietnam before 1969 found marijuana plentiful but little else in the way of illicit drugs (Stanton, 1976). In 1969, heroin and opium began to arrive on the scene, and by these opiates were very widely available...heroin and opium were relatively cheap and very pure, so pure that the soldiers could get ample effect by smoking heroin in combination with Tobacco or marijuana. This made opiates appealing to men who would have been reluctant to inject them. At the height of the use of opiates, in 1971, almost half the army's enlisted men had tried them; of those who tried them, about half used enough to develop the hallmarks of addictiontolerance and Withdrawal symptoms (Robins et al., 1975). Extracted from Wikipedia

20 Vietnam was veterans are now in their 70 ies (baby boomers) average survival for men in the US 75a Assuming 1,000,000 veterans with an infection rate of 25%= 250,000 with hepatitis C

21 How genotype 3a came to Europe Goa beach Beatles visisting the ashram of Maharishi Mahesh Yogi.

22 N Spont. clearance 10-30% Liver mortality ~10%/40a

23 CDC million people in the US infected with HCV 46% due to drug abuse Infections through the medical system ( ) n=276!

24 UN General Assembly Special Session on the World Drug Problem 4/16 The report found nearly 250 million people between the ages of 15 and 64 used at least one drug in Although this figure has not grown over the past four years in proportion to the global population, the number of people classified as suffering from drug use disorders exceeded 29 million people, compared with 27 million in the previous report. Additionally, around 12 million people inject drugs, with 14 per cent of these living with HIV.

25 Estimated anti- HCV prevalence among PWID. Globally we estimated that 52 3% (95% UI ) of current PWID have been exposed to hepatitis C (anti-hcv positive), equating to 8 2 million ( million) people.. Degenhardt et al. The Lancet Global Health , e ),

26 2013 Introduction of IFN free DAA combinations

27 now N Spont. clearance 10-30%

28 Opioid epidemic USA

29 Epstein et al, ID week 2018

30 ie. Pakistan Compulsory testing of blood transfusions: 2016 No medical infrastructure in rural areas Political instability No hygienic regulations for barbers Mill. people, ~up to 8% of adults anti-hcv + > 7 Mill affected - Action needed!

31 ie. Austria Compulsory testing of blood transfusions: 1992 Many physicians available, Estimated max. n of HCV infected 28,000, about 15,000 SVR, many on treatment Legal hygienic regulations for barbers.. 8 Mill. people, 0.1% of adults anti-hcv pos! Screening of risk groups enough Estimate number of HCV+ subjects outside of risk groups : < 1000

32 Take home message Numbers on HCV-infected persons unreliable, based on limited data High regional variation route of infection availabilty of trained doctors availabilty of treatment

PREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS

PREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS PREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS Holly Hagan, PhD Professor Co-Director, Center for Drug Use and HIV Research Principal Investigator, HCV Synthesis Project New York University HCV prevalence

More information

Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT

Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT Background and affiliations BS (MIT); 3 years in international health (Mexico City and Honduras with Peace Corps); MS (Colorado State University);

More information

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at: ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis

More information

RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS

RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS The International Network on Hepatitis in Substance users (INHSU) Olav Dalgard Oslo Grebely J et al Int J

More information

Modelling the Impact of Interventions Targeting High- Risk Populations on the HCV Epidemic in Resource- Limited Settings Pakistan as a Case Study

Modelling the Impact of Interventions Targeting High- Risk Populations on the HCV Epidemic in Resource- Limited Settings Pakistan as a Case Study 1 Modelling the Impact of Interventions Targeting High- Risk Populations on the HCV Epidemic in Resource- Limited Settings Pakistan as a Case Study Aaron G. Lim, Matthew Hickman, Peter Vickerman Population

More information

Hepatitis is an epidemic disease that can be caused by different viruses including hepatitis viruses A, B, C, D or E.

Hepatitis is an epidemic disease that can be caused by different viruses including hepatitis viruses A, B, C, D or E. What is Hepatitis? Hepatitis is an epidemic disease that can be caused by different viruses including hepatitis viruses A, B, C, D or E. Hepatitis A and E are not chronic and are mostly present in areas

More information

Hepa%%s E Virus Is it a Concern?

Hepa%%s E Virus Is it a Concern? IPFA/PEI 17 th Workshop on Surveillance and Screening of Blood Borne Pathogens 26-27 May 2010, The Regent Esplanade Zagreb Hotel, Zagreb, Croa%a Hepa%%s E Virus Is it a Concern? Keiji Matsubayashi Hokkaido

More information

Version for the Silent Procedure 29 April Agenda item January Hepatitis

Version for the Silent Procedure 29 April Agenda item January Hepatitis Version for the Silent Procedure 29 April 2014 134th session EB134.R18 Agenda item 10.5 25 January 2014 Hepatitis The Executive Board, Having considered the report on hepatitis, 1 RECOMMENDS to the Sixty-seventh

More information

Hepatitis C. Core slides

Hepatitis C. Core slides Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and

More information

Hepatitis C in Australia:

Hepatitis C in Australia: Hepatitis C in Australia: Epidemiology and Clinical Presentation (and a bit of virology ) A/Prof Mark Douglas Hepatitis C - Distribution Te and Jensen 2010 Clin Liver Dis Hepatitis C Epidemiology Estimated

More information

The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015

The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015 The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015 December 21, 2015 2 December 21, 2015 3 Can we eliminate hepatitis C? Treatments December 21, 2015 4 We Have the Roadmap

More information

Is Elimination of Hepatitis C Possible?

Is Elimination of Hepatitis C Possible? Is Elimination of Hepatitis C Possible? JORGE MERA, MD CHEROKEE NATION DISCLOSURE INFORMATION The presenter has nothing to disclose. Outline Scope of the problem Definitions Is elimination of HCV needed?

More information

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route

More information

PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases

PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases Viruses in July (ViJ), 2004 Overview Epidemiology Perinatal transmission

More information

Hepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003

Hepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003 Hepatitis 2003 STARS Program Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003 Outline n Hepatitis A Epidemiology and screening Transmission n Hepatitis B Epidemiology

More information

Hepatitis C: Let s Talk About It. Causes of Hepatitis

Hepatitis C: Let s Talk About It. Causes of Hepatitis Hepatitis C: Let s Talk About It Susan Thompson, RN, MPH Technical Assistance and Training Program NC Communicable Disease Branch July 2012 Causes of Hepatitis any swelling, inflammation, or irritation

More information

Management of Chronic HCV 2017 and Beyond

Management of Chronic HCV 2017 and Beyond Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence

More information

Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious Disease & Laboratory Sciences

Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious Disease & Laboratory Sciences Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious

More information

Obstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis

Obstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis Obstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease Control and

More information

Healthy Liver Cirrhosis

Healthy Liver Cirrhosis Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The

More information

Update on HIV-HCV Epidemiology and Natural History

Update on HIV-HCV Epidemiology and Natural History Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,

More information

Hepatitis E in South Africa. Tongai Maponga

Hepatitis E in South Africa. Tongai Maponga Hepatitis E in South Africa Tongai Maponga 7th FIDSSA CONGRESS 2017 This is what usually comes to mind History of hepatitis E virus An ET-NANB hepatitis virus later named HEV was first suspected in 1980.

More information

Hepatitis C in the WHO European Region

Hepatitis C in the WHO European Region Hepatitis C in the WHO European Region Antons Mozalevskis WHO Regional Office for Europe Drug-related infectious disease (DRID) annual expert meeting 15 16 June 2015, EMCDDA Lisbon Burden of viral hepatitis

More information

HIV and HCV coinfection - Barriers in Central and Eastern Europe

HIV and HCV coinfection - Barriers in Central and Eastern Europe HIV and HCV coinfection - Barriers in Central and Eastern Europe Jerzy Jaroszewicz Vice President of Polish Association for the Study of Liver Department of Infectious Diseases and Hepatology, Medical

More information

Section 7: Providing HCV testing and treatment to people who inject drugs

Section 7: Providing HCV testing and treatment to people who inject drugs Section 7: Providing HCV testing and treatment to people who inject drugs Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective

More information

New recommendations for immunocompromised patients

New recommendations for immunocompromised patients New recommendations for immunocompromised patients Hepatitis E Virus (HEV): Transmission, incidence and presentation Emerging evidence regarding HEV transmission from blood components and dietary consumption

More information

Epidemiology of blood-borne Infections in Vietnam

Epidemiology of blood-borne Infections in Vietnam IPFA 4 th Asia Workshop on Plasma Quality and Supply Epidemiology of blood-borne Infections in Vietnam Nguyen Thị Lan Anh MD, PhD Center for Bio-Medical Rsearch Screening donated blood for infections:

More information

Bible Class: HCV Infection

Bible Class: HCV Infection Bible Class: HCV Infection PD Dr. Dr. med. Nasser Semmo UVCM, Hepatology What is the HCV prevalence and incidence? 2 HCV Prevalence Worldwide about 120-210 Mio. infected with HCV, about 9 Mio. in Europe,

More information

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology

More information

Practical Solutions to Reduce Incidence of Liver Cancer. Nancy Steinfurth, Executive Director Liver Health Connection November 2017

Practical Solutions to Reduce Incidence of Liver Cancer. Nancy Steinfurth, Executive Director Liver Health Connection November 2017 Practical Solutions to Reduce Incidence of Liver Cancer Nancy Steinfurth, Executive Director Liver Health Connection November 2017 Prevention HBV Vaccinate for hepatitis B Costs between $120 and $370 if

More information

Uses and Misuses of Viral Hepatitis Testing. Origins of Liver Science

Uses and Misuses of Viral Hepatitis Testing. Origins of Liver Science Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness

More information

Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre

Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural

More information

Perinatal Transmission of Hepatitis C Virus

Perinatal Transmission of Hepatitis C Virus Perinatal Transmission of Hepatitis C Virus Vienna, 1 June 2017 VHPB MEETING Giuseppe Indolfi Meyer Children s University Hospital of Florence Perinatal Transmission of Hepatitis C Virus Outline definition

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis

More information

Statement of the Executive Director UNODC on International Day against Drug Abuse and Illicit Trafficking

Statement of the Executive Director UNODC on International Day against Drug Abuse and Illicit Trafficking Statement of the Executive Director UNODC on International Day against Drug Abuse and Illicit Trafficking 26 June 2013 The International Day against Drug Abuse and Illicit Trafficking is a suitable day

More information

Bruce A. Luxon, MD, PhD, FACG Consultant: Vertex Speakers Bureau: Merck

Bruce A. Luxon, MD, PhD, FACG Consultant: Vertex Speakers Bureau: Merck Bruce A. Luxon, MD, PhD, FACG Consultant: Vertex Speakers Bureau: Merck Bruce A. Luxon, MD, Ph.D. Anton and Margaret Fuisz Chair in Medicine Professor and Chair Department of Medicine Georgetown University

More information

Cases: Issues in Hepatitis C in Active or Recently Active Substance Abuse and Renal Failure

Cases: Issues in Hepatitis C in Active or Recently Active Substance Abuse and Renal Failure Cases: Issues in Hepatitis C in Active or Recently Active Substance Abuse and Renal Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts

More information

HCV elimination : lessons from Scotland

HCV elimination : lessons from Scotland HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from

More information

CHALLENGES IN THE ELIMINATION OF HEPATITIS VIRUSES: THE ALASKA STORY AND BEYOND

CHALLENGES IN THE ELIMINATION OF HEPATITIS VIRUSES: THE ALASKA STORY AND BEYOND CHALLENGES IN THE ELIMINATION OF HEPATITIS VIRUSES: THE ALASKA STORY AND BEYOND Brian J McMahon MD Clinical and Medical Director Liver Disease & Hepatitis Program ANTHC and Research Associate, CDC Alaska

More information

The Changing World of Hepatitis C

The Changing World of Hepatitis C The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures

More information

Hepatitis C reinfection after sustained virological response in HIV/HCV co-infected patients

Hepatitis C reinfection after sustained virological response in HIV/HCV co-infected patients Hepatitis C reinfection after sustained virological response in HIV/HCV co-infected patients Fábio Videira Santos, Joana Fragoso, Ana Cipriano, Miguel Araújo Abreu, Olga Vasconcelos, Ana Aboim Horta, Ana

More information

Viral Hepatitis. WHO Regional Office for Europe July 2013

Viral Hepatitis. WHO Regional Office for Europe July 2013 Viral Hepatitis WHO Regional Office for Europe July 2013 What is Hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D,

More information

4th International HIV/Viral Hepatitis Co- Infection Meeting

4th International HIV/Viral Hepatitis Co- Infection Meeting INSTITUTIONAL STRAPLINE 4th International HIV/Viral Hepatitis Co- Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Approaches for simplified HCV diagnostics and screening algorithms: thoughts

More information

Notes Setting the Scene

Notes Setting the Scene We need to know who is at risk of Hepatitis B and C infections so that we can identify them and offer them testing. Primary care has important roles in diagnosing patients but also after diagnosis, helping

More information

@PremierHA #AdvisorLive. Download today s slides at

@PremierHA #AdvisorLive. Download today s slides at @PremierHA #AdvisorLive Download today s slides at www.premierinc.com/events Logistics Audio Use your computer speakers or dial in with the number on your screen Notes Download today s slides from the

More information

Strategies to Address HCV

Strategies to Address HCV Strategies to Address HCV HIV Programs & U.S. Viral Hepatitis Action Plan Corinna Dan, RN, M.P.H. Viral Hepatitis Policy Advisor Office of HIV/AIDS and Infectious Disease Policy September 10, 2015 1 The

More information

Update on HCV Treatment

Update on HCV Treatment Update on HCV Treatment Ajay Bharti, MD Associate Professor of Medicine Division of Infectious Diseases University of California San Diego 2018 April 28, 2018 Clinically relevant questions in HCV-HIV coinfected

More information

Monitoring the HCV care cascade to inform public health action

Monitoring the HCV care cascade to inform public health action Monitoring the HCV care cascade to inform public health action Susan Hariri, PhD Division of Viral Hepatitis Centers for Disease Control and Prevention NASTAD Hepatitis Technical Assistance Meeting Washington

More information

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis

More information

Hepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011

Hepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment

More information

Viral hepatitis and Hepatocellular Carcinoma

Viral hepatitis and Hepatocellular Carcinoma Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C

More information

CURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS

CURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS CURING HEPATITIS C IN GENERAL PRACTICE: THE FIRST 60 DAYS Baker D 1,2, McMurchie M 1, Rodgers C 1, Farr V 1, Williams M 1 1 East Sydney Doctors, 2 Australasian Society for HIV Medicine 1 Disclosures Advisory

More information

Epidemiology of Hepatitis C Boston, 2015 Craig Regis, MPH Infectious Disease Bureau Boston Public Health Commission

Epidemiology of Hepatitis C Boston, 2015 Craig Regis, MPH Infectious Disease Bureau Boston Public Health Commission Epidemiology of Hepatitis C Boston, 2015 Craig Regis, MPH Infectious Disease Bureau Boston Public Health Commission Picture from http://hepcsupport.org/ 2014 Overview Case definitions Local data Demographics

More information

Clinical Infectious Diseases Advance Access published September 3, 2014

Clinical Infectious Diseases Advance Access published September 3, 2014 Clinical Infectious Diseases Advance Access published September 3, 2014 1 Acute hepatitis C virus infection in HIV+ MSM: Should we change our screening practice? Reiberger T. Division of Gastroenterology

More information

The Alphabet Soup of Viral Hepatitis Testing

The Alphabet Soup of Viral Hepatitis Testing The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,

More information

Strategies to Improve Viral Hepatitis Prevention, Care and Treatment through Appropriations. Emily McCloskey USCA October 3, 2014

Strategies to Improve Viral Hepatitis Prevention, Care and Treatment through Appropriations. Emily McCloskey USCA October 3, 2014 Strategies to Improve Viral Hepatitis Prevention, Care and Treatment through Appropriations Emily McCloskey USCA October 3, 2014 About NASTAD NASTAD is an international non-profit association of U.S. state

More information

National Viral Hepatitis Action Plan Priority Populations Approach

National Viral Hepatitis Action Plan Priority Populations Approach National Viral Hepatitis Action Plan Priority Populations Approach November 29, 2017 Corinna Dan, RN, MPH Office of HIV/AIDS and Infectious Disease Policy Office of the Assistant Secretary for Health Department

More information

Hepatitis C Virus (HCV)

Hepatitis C Virus (HCV) Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are

More information

Hepatitis C Best Practice Guidelines For Local Health Departments

Hepatitis C Best Practice Guidelines For Local Health Departments Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have

More information

HEPATITIS ELIMINATION IN SUB-SAHARAN AFRICA: WHAT WILL IT TAKE?

HEPATITIS ELIMINATION IN SUB-SAHARAN AFRICA: WHAT WILL IT TAKE? HEPATITIS ELIMINATION IN SUB-SAHARAN AFRICA: WHAT WILL IT TAKE? Ganiyat Kikelomo OYELEKE FMCP Hepatologist & Gastroenterologist Lagos University Teaching Hospital, Nigeria. INTEREST 2018, KIGALI CONFERENCE

More information

Epidemiology of Hepatitis C Iran

Epidemiology of Hepatitis C Iran Seyed Moayed Alavian M.D. Professor of Gastro & Hepatology Editor-in-chief of Glob Hepat Comm Editor-in-chief of Hepatitis Monthly E mail: editor@hepatmon.com Epidemiology of Hepatitis C Iran Epidemiology

More information

Hepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD

Hepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD Hepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD Director, Program for Viral Hepatitis Elimination, Task Force for Global Health Senior Scientist, National Center for HIV/AIDS,

More information

We need to know who is at risk of Hepatitis B and C infections so that we can identify them and offer them testing. Primary care has important roles

We need to know who is at risk of Hepatitis B and C infections so that we can identify them and offer them testing. Primary care has important roles 0 We need to know who is at risk of Hepatitis B and C infections so that we can identify them and offer them testing. Primary care has important roles in diagnosing patients but also after diagnosis, helping

More information

The Global Burden of Viral Hepatitis

The Global Burden of Viral Hepatitis The Global Burden of Viral Hepatitis Benjamin Cowie WHO Collaborating Centre for Viral Hepatitis Victorian Infectious Diseases Reference Laboratory Doherty Institute, University of Melbourne benjamin.cowie@mh.org.au

More information

ARISTOTLE HCV-HIV: A fast-track intervention to seek-test-link-treat PWID in Athens, Greece

ARISTOTLE HCV-HIV: A fast-track intervention to seek-test-link-treat PWID in Athens, Greece IVHEM, 6-7 December 2018 ARISTOTLE HCV-HIV: A fast-track intervention to seek-test-link-treat PWID in Athens, Greece Vana Sypsa Department of Hygiene, Epidemiology and Medical Statistics Medical School,

More information

ORAL MANIFESTATIONS IN LIVER DISEASES

ORAL MANIFESTATIONS IN LIVER DISEASES ORAL MANIFESTATIONS IN LIVER DISEASES Rodica Ghiuru, D.Munteanu Department of Internal Medicine Abstract: Chronic hepatitis C infection is a worldwide health problem because it causes chronic hepatitis,

More information

Impact of Screening and Treatment for Hepatitis C Virus (HCV) Infection in Switzerland

Impact of Screening and Treatment for Hepatitis C Virus (HCV) Infection in Switzerland 1 Impact of Screening and Treatment for Hepatitis C Virus (HCV) Infection in Switzerland A Comprehensive Mathematical Model of the Swiss HCV Epidemic Final report Janne Estill*, Maryam Sadeghimehr*, Olivia

More information

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,

More information

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections

More information

HEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014

HEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014 HEPATITIS C UPDATES Sanaa S. Said 10 th April, 2014 CONTENTS Introduction Epidemiology Transmission and Natural history Kenyan guidelines What is new? References INTRODUCTION Hepacivirus genus, Flaviviridae

More information

Viral Hepatitis in Reproductive Health

Viral Hepatitis in Reproductive Health Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology

More information

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines

More information

Lifetime risk of infection >60% Early childhood infections common

Lifetime risk of infection >60% Early childhood infections common Hepatitis Community Medicine HBV Public health sig HBV is 100 times more infectious than HIV. >350 million chronically infected worldwide. >1 million people die annually of HBV- related chronic liver disease.

More information

EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE

EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE E. Angeli, A. Mainini, C. Atzori, G. Gubertini and G. Rizzardini II Dept. Infectious

More information

Numbers HCV and HIV Epidemiology in the US

Numbers HCV and HIV Epidemiology in the US By The Numbers HCV and HIV Epidemiology in the US Coinfection Fridays Session 1 18 January 2019 Christopher B. Hurt, MD Associate Professor of Medicine Co-Director, North Carolina AIDS Training & Education

More information

Improving Access & Linkage to Care in Underserved Populations & Baby Boomers

Improving Access & Linkage to Care in Underserved Populations & Baby Boomers Improving Access & Linkage to Care in Underserved Populations & Baby Boomers Lesley Miller MD Medical Director, Grady Liver Clinic Associate Professor of Medicine Division of General Medicine and Geriatrics

More information

Hepatitis C Elimination Program Georgia

Hepatitis C Elimination Program Georgia Hepatitis C Elimination Program Georgia Maia Butsashvili, MD, MS, PhD Health Research Union (HRU)/Clinic NEOLAB National HCV Committee International School of Public Health High prevalence of HCV in Georgia

More information

New York State HCV Provider Webinar Series

New York State HCV Provider Webinar Series New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Dost Sarpel, MD Division of Infectious Disease Viral Hepatology Milford Regional Medical Center Objectives Review the epidemiology

More information

Setting the Stage Key Challenges in Elimination

Setting the Stage Key Challenges in Elimination Setting the Stage Key Challenges in Elimination Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto Disclosures Consulting: Abbvie, Contravir,

More information

The Global Movement to Eliminate Viral Hepatitis. John W Ward, MD Task Force for Global Health CDC, Atlanta, Georgia, USA

The Global Movement to Eliminate Viral Hepatitis. John W Ward, MD Task Force for Global Health CDC, Atlanta, Georgia, USA The Global Movement to Eliminate Viral Hepatitis John W Ward, MD Task Force for Global Health CDC, Atlanta, Georgia, USA Infection and Disease Control, Elimination and Eradication Control Below acceptable

More information

ADDRESSING VIRAL HEPATITIS IN PEOPLE WITH SUBSTANCE USE DISORDERS: A THREE (3) PART SERIES

ADDRESSING VIRAL HEPATITIS IN PEOPLE WITH SUBSTANCE USE DISORDERS: A THREE (3) PART SERIES ADDRESSING VIRAL HEPATITIS IN PEOPLE WITH SUBSTANCE USE DISORDERS: A THREE (3) PART SERIES David Njabulo Whiters, PhD, MSW, NCAC II Consultant, Great Lakes Addiction Technology Transfer Center Setting

More information

NATURAL HISTORY OF HEPATITIS B

NATURAL HISTORY OF HEPATITIS B NATURAL HISTORY OF HEPATITIS B AND DIAGNOSTIC: STATE OF THE ART O. BAHRI LABORATORY OF MEDICAL BIOLOGY AZIZA OTHMANA HOSPITAL TUNIS, TUNISIA The 2 nd Congress of The Federation of Arab Societies of Clinical

More information

VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...

VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND... 8 April 2014 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH PROGRAMME SUBCOMMITTEE Sixty-fourth session Brazzaville, Republic of Congo, 9 11 June 2014 Provisional agenda item 6 VIRAL HEPATITIS: SITUATION

More information

Detection of Hepatitis B and C in Primary Care

Detection of Hepatitis B and C in Primary Care Detection of Hepatitis B and C in Primary Care Presentation 2 January 2016 Quality Quality Education Education for for aa Healthier Healthier Scotland Scotland 1 1 Learning Outcomes Participants will be

More information

JMSCR Volume 03 Issue 01 Page January 2015

JMSCR Volume 03 Issue 01 Page January 2015 www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Seroprevalence of HBV among HIV Patients and Blood Donors Author Dr. Vedavati B I 1, Dr. Amrutha Kumari B 2, Dr. Venkatesha D 3 Mysore

More information

Epidemiology of hepatitis B and D in Greece

Epidemiology of hepatitis B and D in Greece Epidemiology of hepatitis B and D in Greece George V. Papatheodoridis Assistant Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University Medical School, Hippokration

More information

Curing Hepatitis C: Current And Future Options For Treatment By Gregory T. Everson, Gene Schiff READ ONLINE

Curing Hepatitis C: Current And Future Options For Treatment By Gregory T. Everson, Gene Schiff READ ONLINE Curing Hepatitis C: Current And Future Options For Treatment By Gregory T. Everson, Gene Schiff READ ONLINE AASLD president will discuss current hepatitis B treatment options, to hepatitis C research,

More information

Viral Hepatitis: A Global Snapshot of Challenges and Opportunities

Viral Hepatitis: A Global Snapshot of Challenges and Opportunities Viral Hepatitis: A Global Snapshot of Challenges and Opportunities John W. Ward, MD, Division of Viral Hepatitis U.S. Centers for Disease Control and Prevention Division of Viral Hepatitis National Center

More information

VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...

VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND... 5 November 2014 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Sixty-fourth session Cotonou, Republic of Benin, 3 7 November 2014 Provisional agenda item 11 VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES

More information

HCV Infection in the United States

HCV Infection in the United States New York State Department of Health HCV Infection in the United States ~4 million in the U.S. infected with chronic hepatitis C virus (HCV) 17,000 new infections per year 75 percent of adults with hepatitis

More information

i Screening and Natural History

i Screening and Natural History HCV Epidemiology, i Screening and Natural History BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Hepatitis

More information

Viral Hepatitis Burden and Policy Directions in the European Region of WHO

Viral Hepatitis Burden and Policy Directions in the European Region of WHO Viral Hepatitis Burden and Policy Directions in the European Region of WHO Dr Nedret Emiroglu WHO Regional Office for Europe Brussels 14-15 October 2010 Global Burden of Chronic Viral Hepatitis 2.7% all

More information

The Counselling of Blood Donors Identified as HIV Reactive. A Review as from January 2007 until June 2011

The Counselling of Blood Donors Identified as HIV Reactive. A Review as from January 2007 until June 2011 The Counselling of Blood Donors Identified as HIV Reactive A Review as from January 2007 until June 2011 The Blood Transfusion Service of Namibia Dr. Regine Redecker Mr. Tinus Matyayi 2 3 Background -TTI

More information

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID 2 nd Meeting on detecting and responding to outbreaks of HIV among PWID Update on country situation: AUSTRIA Lisbon, 12 th October 201 Epidemiological update 2 HIV notifications in PWID Number of HIV cases

More information

Viral Hepatitis B and C in North African Countries

Viral Hepatitis B and C in North African Countries Viral Hepatitis B and C in North African Countries Prevalence, Risk factors and How to prevent Prof. Ossama Rasslan President, ESIC ICAN, Vice-Chair ICAN 2014, Harare, Zimbabwe, Nov 3rd 5th Overview Viral

More information

Prevention and control of hepatitis B and C in the European Region of WHO

Prevention and control of hepatitis B and C in the European Region of WHO Prevention and control of hepatitis B and C in the European Region of WHO Viral Hepatitis Prevention Board Dr Nedret Emiroglu WHO Regional Office for Europe Burden of viral hepatitis in the European Region

More information

INTRAVENOUS INJECTING DRUG USE.

INTRAVENOUS INJECTING DRUG USE. Injecting drug users in Europe Towards an educational approach Lucas Wiessing European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon lucas.wiessing@ emcdda.org www.emcdda.org It has been

More information

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38 2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally

More information

Treatment and Access to Drugs

Treatment and Access to Drugs Treatment and Access to Drugs Presenter: Co-leads: Peter Beyer & Philippa Easterbrook WHO Regional Advisor for South East Asia (SEARO): Razia Narayan Pendse Session Objectives By the end of this session,

More information